Why is this study being conducted?
The purpose of the study is to evaluate a potential new vaccine for prevention against the newer variants of COVID-19. In this study, the investigational vaccine will be given with an approved flu vaccine.
Who is eligible to participate in this study?
You may be eligible if you:
- Are over 18 years of age
- Have received at least 3 doses of COVID-19 vaccines (first two doses and the latest booster dose was Pfizer-BioNTech or Moderna vaccine)
- Had your last dose of a COVID-19 vaccine more than 5 months ago
Applicants who express interest in participating in this study will be reviewed and contacted as other requirement criteria must also be met.
What happens during the study?
Trial duration will be up to 6 months and participants will have about 4 trial visits
Trial site visits will occur at the Griffith University Clinical Trial Unit on the Gold Coast.
You will receive 1 dose of the study vaccine, 1 dose of influenza vaccine and 1 dose of placebo over the course of the study.
You will have 1 safety phone call.
Volunteer to participate
Participation in this study is completely voluntary, and participants can decide to withdraw at any time.
Eligible participants will be reimbursed for their time and travel associated with each study visit.
Contact Haewon Park
For more information about this clinical trial contact:
Haewon Park, Clinical Trial Coordinator.
07 5678 0350 clinicaltrialunit@griffith.edu.au
This study has been approved by Bellberry Limited #2023-11-1366 and GU HREC #2024/150.
Can't see a trial for you?
Join our volunteer database to be contacted about new clinical trials